Inferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma

von Xie, Yi, Jia, Mengyu, Shi, Jumei, Tao, Yi
Veröffentlicht in Cancer Med (2020)

Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma

von Wu, Xiaosong, Tao, Yi, Hou, Jun, Meng, Xiuqin, Shi, Jumei
Veröffentlicht 2012

Smoldering Multiple Myeloma

von Gao, Minjie, Yang, Guang, Kong, Yuanyuan, Wu, Xiaosong, Shi, Jumei
Veröffentlicht in Biomed Res Int (2015)

Multiple myeloma cancer stem cells

von Gao, Minjie, Kong, Yuanyuan, Yang, Guang, Gao, Lu, Shi, Jumei
Veröffentlicht in Oncotarget (2016)

Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome

von Jia, Xinyan, Yang, Wenzhong, Zhou, Xiaohui, Han, Lu, Shi, Jumei
Veröffentlicht in Oncol Lett (2020)

Down-Regulation of 11β-Hydroxysteroid Dehydrogenase Type 2 by Bortezomib Sensitizes Jurkat Leukemia T Cells against Glucocorticoid-Induced Apoptosis

von Tao, Yi, Gao, Lu, Wu, Xiaosong, Wang, Hongmei, Yang, Guang, Zhan, Fenghuang, Shi, Jumei
Veröffentlicht 2013

Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials

von Gao, Minjie, Gao, Lu, Yang, Guang, Tao, Yi, Tompkins, Van S, Wu, Xiaosong, Xu, Hongwei, Zhan, Fenghuang, Shi, Jumei
Veröffentlicht 2014

Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of rando...

von Gao, Minjie, Yang, Guang, Han, Ying, Kong, Yuanyuan, Wu, Huiqun, Tao, Yi, Zhan, Fenghuang, Shi, Jumei, Wu, Xiaosong
Veröffentlicht in Int J Clin Exp Med (2015)

Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation

von Gu, Zhimin, Wang, He, Xia, Jiliang, Yang, Ye, Jin, Zhendong, Xu, Hongwei, Shi, Jumei, De Domenico, Ivana, Tricot, Guido, Zhan, Fenghuang
Veröffentlicht in Cancer Res (2015)

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3

von Wang, Houcai, Xie, Bingqian, Kong, Yuanyuan, Tao, Yi, Yang, Guang, Gao, Minjie, Xu, Hongwei, Zhan, Fenghuang, Shi, Jumei, Zhang, Yiwen, Wu, Xiaosong
Veröffentlicht in Oncotarget (2016)

Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity

von Yang, Fengqiang, Shao, Yang, Yang, Fengping, Liu, Ming, Huang, Jianhua, Zhu, Kai, Guo, Changcheng, Luo, Jun, Li, Wei, Yang, Bin, Shi, Jumei, Zheng, Junhua
Veröffentlicht 2013

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials

von Gao, Minjie, Yang, Guang, Tompkins, Van S., Gao, Lu, Wu, Xiaosong, Tao, Yi, Hu, Xiaojing, Hou, Jun, Han, Ying, Xu, Hongwei, Zhan, Fenghuang, Shi, Jumei
Veröffentlicht 2014

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

von Gao, Lu, Gao, Minjie, Yang, Guang, Tao, Yi, Kong, Yuanyuan, Yang, Ruixue, Meng, Xiuqin, Ai, Gongwen, Wei, Rong, Wu, Huiqun, Wu, Xiaosong, Shi, Jumei
Veröffentlicht in Biomed Res Int (2015)

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

von Wu, Xiaosong, Shi, Jumei, Wu, Yi, Tao, Yi, Hou, Jun, Meng, Xiuqin, Hu, Xiaojing, Han, Ying, Jiang, Wei, Tang, Siyuan, Zangari, Maurizio, Tricot, Guido, Zhan, Fenghuang
Veröffentlicht 2010

RARα2 expression confers myeloma stem cell features

von Yang, Ye, Shi, Jumei, Tolomelli, Giulia, Xu, Hongwei, Xia, Jiliang, Wang, He, Zhou, Wen, Zhou, Yi, Das, Satyabrata, Gu, Zhimin, Levasseur, Dana, Zhan, Fenghuang, Tricot, Guido
Veröffentlicht 2013

ALDH1 Activity Identifies Tumor Initiating Cells and Links to Chromosomal Instability Signatures in Multiple Myeloma

von Zhou, Wen, Yang, Ye, Gu, Zhimin, Wang, He, Xia, Jiliang, Wu, Xiaosong, Zhan, Xin, Levasseur, Dana, Zhou, Yi, Janz, Siegfried, Tricot, Guido, Shi, Jumei, Zhan, Fenghuang
Veröffentlicht 2013

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

von Yang, Guang, Gao, Minjie, Zhang, Yiwen, Kong, Yuanyuan, Gao, Lu, Tao, Yi, Han, Ying, Wu, Huiqun, Meng, Xiuqin, Xu, Hongwei, Zhan, Fenghuang, Wu, Xiaosong, Shi, Jumei
Veröffentlicht in Oncotarget (2015)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma

von Gao, Minjie, Chen, Gege, Wang, Houcai, Xie, Bingqian, Hu, Liangning, Kong, Yuanyuan, Yang, Guang, Tao, Yi, Han, Ying, Wu, Xiaosong, Zhang, Yiwen, Dai, Bojie, Shi, Jumei
Veröffentlicht in Oncotarget (2016)

Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma

von Kong, Yuanyuan, Hu, Liangning, Lu, Kang, Wang, Yingcong, Xie, Yongsheng, Gao, Lu, Yang, Guang, Xie, Bingqian, He, Wan, Chen, Gege, Wu, Huiqun, Wu, Xiaosong, Zhan, Fenghuang, Shi, Jumei
Veröffentlicht in Cell Death Dis (2019)

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myeloma

von Shi, Jumei, Tricot, Guido J., Garg, Tarun K., Malaviarachchi, Priyangi A., Szmania, Susann M., Kellum, Rachel E., Storrie, Brian, Mulder, Arend, Shaughnessy, John D., Barlogie, Bart, van Rhee, Frits
Veröffentlicht 2008